Business briefs: Takeda, Stryker

Share this article:

Takeda scored an approvals hat-trick Friday with the FDA's Friday approval of the active ingredient alogliptin (AKA Nesina) as a stand-alone treatment for type 2 diabetes—as well as alogliptin-metformin combination Kazano and alogliptin-pioglitazone combo Oseni.

Stryker is solidifying its Asian footprint. The Michigan device maker announced this month that it is buying out Asia-based Trauson Holdings for $764 million in cash. The firms have been working together since 2007. “The acquisition of Trauson is a critical step toward broadening our presence in China and developing a value segment platform for the emerging markets,” Stryker President and CEO Kevin Lobo said in a statement. The announcement also noted that Trauson is a major competitor. The deal is expected to close by the end of the second quarter.
Share this article:
You must be a registered member of MMM to post a comment.

This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.